Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$74.76 USD

74.76
485,354

-0.88 (-1.16%)

Updated Nov 7, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access

by Zacks Equity Research

This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.

AngioDynamics IDE Application for NanoKnife Gets FDA Nod

by Zacks Equity Research

AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.

    Hologic Breast Health Arm Aids Strongly, Rising Costs Ail

    by Zacks Equity Research

    Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.

    Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?

    by Zacks Equity Research

    Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.

    ResMed Study Shows Remote Monitoring Benefits on CPAP Use

    by Zacks Equity Research

    Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.

    Here's Why You Should Buy Masimo (MASI) Stock Right Now

    by Zacks Equity Research

    Masimo (MASI) benefits from launches like Halo ION.

    Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects

    by Zacks Equity Research

    Avedro (AVDR) gains from promising developments in recent times.

    Varian Medical's CTSI Buyout to Boost Oncology Services Unit

    by Zacks Equity Research

    The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.

    Why Should You Hold on to Myriad Genetics (MYGN) Stock?

    by Zacks Equity Research

    Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

    LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses

    by Zacks Equity Research

    LabCorp's (LH) diagnostics business grows organically despite additional price reductions.

    Medtronic (MDT) Launches Telescope Guide Extension Catheter

    by Zacks Equity Research

    The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.

    ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

    by Zacks Equity Research

    ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

    QIAGEN Partners Inovio to Develop Companion Diagnostics

    by Zacks Equity Research

    QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

    Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site

    by Zacks Equity Research

    The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.

    Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

    by Zacks Equity Research

    Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

    Varian Medical Installs ProBeam at Research Hub in Singapore

    by Zacks Equity Research

    Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.

    Here's Why You Should Hold on to ResMed (RMD) Stock for Now

    by Zacks Equity Research

    ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.

    Integra LifeSciences Rides on Product Launch, Faces Rivalry

    by Zacks Equity Research

    Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.

    STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise

    by Zacks Equity Research

    STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.

    Medtronic to Acquire Titan Spine for Spine Portfolio Boost

    by Zacks Equity Research

    According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.

    ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals

    by Zacks Equity Research

    ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.

    Abbott Rides on Strong CGM, Poor Rhythm Management Ails

    by Zacks Equity Research

    Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.

    Medtronic's (MDT) EV ICD Pilot Study Results Encourage

    by Zacks Equity Research

    The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.

    Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y

    by Zacks Equity Research

    Nevro's (NVRO) domestic and international revenues fall year over year in Q1.

    Here's Why You Should Invest in Illumina (ILMN) Stock Now

    by Zacks Equity Research

    Illumina (ILMN) has been gaining investor confidence on robust performance.